Neuroinflammation and neuromodulation in neurological diseases

Neuroimmunology is a relatively young science. This discipline has emerged today from the research field as a mature and fully developed innovative research area that integrates not only pure topics of neuroimmunology, but also expands on wider fields such as neuroplasticity, neuronal reserve and neuromodulation in association with clinical events, amongst which behavioral disorders stand out. The Cuban School of Neuroimmunology—a recent meeting that took place in Havana, Cuba—focused on topics based on the molecular mechanisms of neuroinflammation in neurological disorders involving behavioral manifestations, such as multiple sclerosis (MS), autism, cerebellar ataxias, Alzheimer´s disease and stroke among others, as well as on the use of new interventional technologies in neurology. Professor Luis Velazquez, from the Cuban Academy of Sciences, dictated an interesting lecture on Spinocerebellar ataxias, a genetic disorder where recent hypotheses related to the influence of neuroinflammation as a neurobiological factor influencing the progression of this disease have emerged. At the same time, the use of new interventional technologies in neurology was discussed, including those referring to novel disease modifying therapies in the course of MS and the use of transcranial magnetic stimulation in several neurological diseases, the latter reinforcing how interventional strategies in the form of non-invasive bran stimulation can contribute to physical rehabilitation in neurology. This paper summarizes the highlights of the most relevant topics presented during the First Cuban School of Neuroimmunology, organized by the Cuban Network of Neuroimmunology, held in June 2019

Psycho-neuro-immuno-endocrinology and COVID-19

Full text (en español

Niveles de plomo y daño en el ADN en niños con trastornos del espectro autista Lead levels and DNA damage in children with autistic spectrum disorders

Introducción: los trastornos del espectro autista se consideran una familia de alteraciones del neurodesarrollo, caracterizada por dificultades en la comunicación y la interacción social, así como la existencia de un comportamiento estereotipado y repetitivo. Aunque existen varias hipótesis que involucran a factores genéticos y ambientales en su etiopatogenia, la verdadera contribución de estos aún se desconoce. En este estudio se explora la relación entre los niveles séricos de plomo, el daño del ADN y la severidad del autismo. Métodos: se estudiaron 15 niños con el diagnóstico de trastornos del espectro autista entre 4 y 11 años de edad y un grupo control del mismo rango de edad. El coeficiente de inteligencia fue evaluado mediante la prueba de Terman-Merrill y los niños fueron clasificados en dos grados de retardo mental (ligero y moderado/severo). Los niveles de plomo en sangre fueron medidos por espectrometría de masa, mientras que el daño del ADN fue determinado en linfocitos de sangre periférica con el empleo de un ensayo de electroforesis alcalina (ensayo del cometa). Resultados: no se mostró diferencia significativa en los niveles de plomo entre los grupos. El daño del ADN fue mayor en los pacientes autistas en relación con el grupo control, cuya diferencia fue significativa (pIntroduction:autistic spectrum disorders are considered to be a family of neurodevelopmental alterations characterized by difficulty to communicate and interact socially, as well as stereotyped, repetitive behavior. Though several hypotheses involve genetic and environmental factors in the etiopathogeny of this condition, their actual participation is still unknown. The present study explores the relationship between serum lead levels, DNA damage and the severity of autism. Methods: a study was conducted with 15 children 4-11 years old diagnosed with autistic spectrum disorders and a control group from the same age range. The intelligence quotient was measured by the Terman-Merrill test, and children were classified into two degrees of mental retardation (mild and moderate/severe). Blood lead levels were measured by mass spectrometry, whereas DNA damage was determined in peripheral blood lymphocytes using the alkaline electrophoresis assay (the comet assay). Results: this study did not show any significant difference in lead levels between the groups. DNA damage was greater in autistic patients than in the control group, and the difference was significant (p<0.05) when mental retardation severity was considered. Patients with a moderate/severe disorder showed significantly greater DNA damage than those with mild disorders and the control group. Conclusions: results confirm the presence of DNA damage in patients with autistic spectrum disorders, suggesting that this factor could be related to mental retardation severity

Rotating and Neurochemical Activity of Rats Lesioned with Quinolinic Acid and Transplanted with Bone Marrow Mononuclear Cells

Huntington&rsquo;s disease (HD) is an inherited, neurodegenerative disorder that results from the degeneration of striatal neurons, mainly GABAergic neurons. The study of neurochemical activity has provided reliable markers to explain motor disorders. To treat neurodegenerative diseases, stem cell transplants with bone marrow (BM) have been performed for several decades. In this work we determine the effect of mononuclear bone marrow cell (mBMC) transplantation on the rotational behavior and neurochemical activity in a model of Huntington&rsquo;s disease in rats. Four experimental groups were organized: Group I: Control animals (n = 5); Group II: Lesion with quinolinic acid (QA) in the striatum (n = 5); Group III: Lesion with QA and transplant with mBMC (n = 5); Group IV: Lesion with QA and transplant with culture medium (Dulbecco&rsquo;s modified Eagle&rsquo;s medium (DMEM) injection) (n = 5). The rotational activity induced by D-amphetamine was evaluated and the concentration of the neurotransmitter amino acids (glutamate and GABA) was studied. The striatal cell transplantation decreases the rotations induced by D-amphetamine (p &lt; 0.04, Wilcoxon matched pairs test) and improves the changes produced in the levels of neurotransmitters studied. This work suggests that the loss of GABAergic neurons in the brain of rats lesioned with AQ produces behavioral and neurochemical alterations that can be reversed with the use of bone marrow mononuclear cell transplants

Peripheral inflammatory markers contributing to comorbidities in autism

This study evaluates the contribution of peripheral biomarkers to comorbidities and clinical findings in autism. Seventeen autistic children and age-matched typically developing (AMTD), between three to nine years old were evaluated. The diagnostic followed the Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DMS-IV) and the Childhood Autism Rating Scale (CARS) was applied to classify the severity. Cytokine profile was evaluated in plasma using a sandwich type ELISA. Paraclinical events included electroencephalography (EEG) record. Statistical analysis was done to explore significant differences in cytokine profile between autism and AMTD groups and respect clinical and paraclinical parameters. Significant differences were found to IL-1 , IL-6, IL-17, IL-12p40, and IL-12p70 cytokines in individuals with autism compared with AMTD (p < 0.05). All autistic patients showed interictalepileptiform activity at EEG, however, only 37.5% suffered epilepsy. There was not a regional focalization of the abnormalities that were detectable with EEG in autistic patients with history of epilepsy. A higher IL-6 level was observed in patients without history of epilepsy with interictalepileptiform activity in the frontal brain region, p < 0.05. In conclusion, peripheral inflammatory markers might be useful as potential biomarkers to predict comorbidities in autism as well as reinforce and aid informed decision-making related to EEG findings in children with Autism spectrum disorders (ASD)

Peripheral inflammatory markers contributing to comorbidities in autism

This study evaluates the contribution of peripheral biomarkers to comorbidities and clinical findings in autism. Seventeen autistic children and age-matched typically developing (AMTD), between three to nine years old were evaluated. The diagnostic followed the Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DMS-IV) and the Childhood Autism Rating Scale (CARS) was applied to classify the severity. Cytokine profile was evaluated in plasma using a sandwich type ELISA. Paraclinical events included electroencephalography (EEG) record. Statistical analysis was done to explore significant differences in cytokine profile between autism and AMTD groups and respect clinical and paraclinical parameters. Significant differences were found to IL-1 , IL-6, IL-17, IL-12p40, and IL-12p70 cytokines in individuals with autism compared with AMTD (p < 0.05). All autistic patients showed interictalepileptiform activity at EEG, however, only 37.5% suffered epilepsy. There was not a regional focalization of the abnormalities that were detectable with EEG in autistic patients with history of epilepsy. A higher IL-6 level was observed in patients without history of epilepsy with interictalepileptiform activity in the frontal brain region, p < 0.05. In conclusion, peripheral inflammatory markers might be useful as potential biomarkers to predict comorbidities in autism as well as reinforce and aid informed decision-making related to EEG findings in children with Autism spectrum disorders (ASD)